|Bid||286.00 x 100|
|Ask||292.30 x 100|
|Day's range||287.47 - 292.30|
|52-week range||244.28 - 370.57|
|PE ratio (TTM)||24.13|
|Earnings date||23 Apr 2018 - 27 Apr 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||378.90|
As discussed earlier, Pfizer’s (PFE) revenue rose ~1% to $13.7 billion during 4Q17 driven by increased sales of its Innovative Health products. It reflects revenues for both Pfizer’s Innovative Health and Essential Health segments in 4Q17. Pfizer reported a fall of ~4% in its US sales in 4Q17, while its sales outside US markets reported a 5% revenue rise in the quarter.
Biogen will present data from its portfolio of investigational therapies for people with neurodegenerative diseases at the Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting in Torino, Italy .
CAMBRIDGE, Mass.--(BUSINESSWIRE)-- Data builds on Biogen’s core work in Alzheimer’s disease and movement disorders such as Parkinson’s disease and progressive supranuclear palsy New aducanumab Phase 1b ...
Biogen Inc. announced today that it will present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting. A plenary session titled “The Importance of Early Identification and Treatment of Alzheimer’s Disease” will be webcast live on Thursday, March 15, 2018 at 8:00 a.m.
CAMBRIDGE, Mass.--(BUSINESSWIRE)-- Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting. A plenary session ...
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).
Biogen Inc. said Monday it reached a deal to buy a phase-2b-trial-ready schizophrenia treatment, PF-04958242, from Pfizer Inc. for up to $590 million. The deal includes an upfront payment of $75 million ...
Biogen Inc. (Nasdaq: BIIB) announced today an agreement to acquire from Pfizer Inc. (NYSE: PFE) PF-04958242, a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia (CIAS). The purchase will include an upfront payment of $75 million with up to $515 million in additional development and commercialization milestone payments, as well as tiered royalties in the low to mid-teen percentages.
Biogen Inc. announced today an agreement to acquire from Pfizer Inc. PF-04958242, a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia .
Biogen today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA® among pre-symptomatic infants with spinal muscular atrophy .
NEW YORK/TOKYO, March 8 (Reuters) - Merck (Jakarta: 28586808.JK - news) & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses. The deal, under which Lenvima will be developed for several types of cancer alone and in combination with Merck's immunotherapy Keytruda, could be worth up to $5.76 billion to Eisai, but most of that would be contingent on eventual sales.
The FDA is reviewing whether a type of brain inflammation called encephalitis linked to Biogen and AbbVie’s MS drug Zinbryta was a result of a known side effect of the therapy or has another cause, a FDA ...
The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.
The Food and Drug Administration is reviewing whether a type of brain inflammation called encephalitis connected to Biogen Inc. and AbbVie Inc.'s multiple sclerosis drug Zinbryta was a result of known ...
Europe's medicines regulator recommended the immediate suspension and recall of Biogen Inc (NasdaqGS: BIIB - news) and AbbVie Inc (LSE: 0QCV.L - news) 's multiple sclerosis drug Zinbryta, following 12 reports of inflammation of the brain, three of which cases were fatal. Biogen and AbbVie withdrew the drug last week, after the European Medicines Agency (EMA) started an urgent review.
Drugmakers Biogen and AbbVie said they are pulling their new multiple-sclerosis treatment Zinbryta from all global markets after several European patients suffered serious inflammatory brain disorders....
Stocks bounced back in a big way today, with the S&P 500 and Nasdaq Composite both finishing in positive territory, and the Dow Jones Industrial Average almost getting there. This isn't the first MS drug setback we've seen this week: Celgene (CELG) also took a hit when the Food and Drug Administration issued a Refusal to File Letter for ozanimod, leading many analysts to estimate a year's delay for its approval.
Biotechs announce they are pulling multiple sclerosis drug Zinbryta from the market following cases of brain inflammation.